Cabozantinib Plus Atezolizumab or Cabozantinib Alone in Patients With Advanced Non-Small Cell Lung Cancer Previously Treated With an Immune Checkpoint Inhibitor: Results From the Phase 1b COSMIC-021 Study | Publicación